Basal
+60' post ACTH T (nmol/l) 1.1 2.3 A (nmol/l) 4.0 7.0 DHEAS (umol /l ) 4.4 4.1 E2 (pmol/l) 0.11 0.11 170HP (nmol/l) 16.0 177.0
Comparison of DHEAS/El+EI and A/El+E2 gave values comparable to transient pubertal gynaecomastia range for bone age as reported by Moore et a1 (JCEM 1984 58: 492) and in which peripheral conversion of adrenal androgen to El and E2 is suggested as the cause of the condition. It remains unexplained why pre-pubertal gynaecomastia is rare in 21-OHase but not 11p-OHase deficiency.
F.LORENZEN*,G. SCHRODER* and W.G.SIPPELL. Paed. Endocrine Unit, Univ.Dept. of Paediatrics,Kiel, W-Germany. Elevated Prolactin (PRL) and normal gonadotropin levels 122 in salt-wastin, congenital adrenal hyperplasia ( s a H , . Important aims of CAH therapy are normal puberty and gonadal function. To study the hypothalamo-pituitary axis, we applied a combined cnRH/TRH bolus test to 12 patients with SCAH (90, 3dl,age 1.3 to 16.8 yrs, and to a group of 135 age and sex matched normal children (GnRH 60 wg/m2, TRH 100 pg/m2 i.v. ). Plasma LH (IRP 68/40), FSH (IRP 78/549) and PRL (WHO 75/249) were measured by RIA at 0 and 30min. All except one male CAHpt were medically well controlled as shown by plasma androgens, 17-OHP,PRA, bone age and growth rate. Results: All SCAH pts showed normal LH and FSH levels relative to their pubertal stage. PRL in normal children over 2yrs of age ranged from 2.1 -14.8ng/ml (5.5f2.3; Z ? SD) at time 0 and from 7.3-48ng/ml (26.2f8.9) at 30min with no difference in sex, age or stage of puberty. SCAH pts showed significantly higher ( P < 0.001) PRL levels of 7.3-24.5ng/ml (11.4t6.1) at time 0 and of 26.8-100ng/ml (62f 24) at 30min. The highest PRL levels were seen in the postmenarcheal patients. Conclusion: Hyperprolactinaemia and hyperandrogenism so far have been reported in patients with hirsutism but not in patients with CAH. Our patients did show hyperprolactinaemia despite normal androgens. Intermittently increased production of androgens, progestins and/or CRF/ACTH might lead to hypothalamic dysfunction and thus to PRL oversecretion. Congenital adrenal hyperplasia (CAH) due to 21-OHD has been found to be closely linked to the major histocompatibility complex (MHC) and more specifically to HLA-B. A two gene model, one on either side of HLA-D has however been suggested by several authors. W e report studies in a C A H family suggesting that the (or one of the two) 21-OH gene might be centromeric to D. The index patient presented ambiguous genitalia (stage IJJ) but no clinical salt loss ; diagnosis was delayed and progressive virilization developped : at 3 yr 4/12, pubic hair, accelerated growth and bone maturation (5 yr). Diagnostic levels (ng/dl) of testosterone (163) and 17a -OH-progesterone (OHP) (basal = 28690 -114,910 after ACTH) were found. Elevated baseline levels (ng/dl/h) of PRA (1563) further rose after N a restriction (2880) or A C T H (4900). The 3 brothers were clinically normal. HLA typing revealed the first to be heterozygous, the 2nd homozygous normal; the 3rd was found to be HLA identical and MLC identical to the CAH-sister (A C W 6 B57 DR6IAW30 CW BW47 DR2). Microlymphocytotoxicity tests e&luded any recombination getween the A and D loci. Hormonal studies (baseline and ACTH stimulated levels of OHP, progesterone and cortisol) showed a typical heterozygote response in both the mother and brother no 3. Unfortunately, studies of the red cell glyoxalase I (GLO) were not informative. However, a DR-GLO recombination is the likely explanation for the present findings, suggesting a 21-OH locus between DR and GLO loci. L.HAGENXS* and E.M. RTZEN. Ped. Endocr U. Karolinska Hospital, STockholm, Sweden.
121 Neonatally elevated 17-OH-progesterone (17-OHP) in so-called late onset congenital adrenal hyperplasia (21-OHase deficiency). At 23yrs of age a CAH (21-OHasel was diagnosed in a woman complaining of (slight) hirsutlsm and oligomenorrhea. During dexamethasone treatment she went through 3 normal pregnancies. The first child (boy) had a largely elevated 17-OHP at 2 days of age (280nmol/l) but was left untreated. At age seven he was healthy and had normal height and bone age. The second child (girl) when examined at 4 yrs of age showed no virilization, normal heigth and bone age. Both children then showed elevated basal levels of 17-OHP; 16,5 and 29nmol/l which increased to 147 and 220nmol/l 60'after ACTH (0,251~19 iv). The cortisol responsetoACTH was poor (205 to 295nmol/l) for the girl and borderline low (215 to 488) for the boy. The third child was healthy in all mentioned respects. The three affected members of the family fell within the range of individuals with acquired or cryptic CAH ( M.I. New et al. J.Clin.Endocr. Metab. 57:320 (1983) . HLA typing of the family was consistent wlth the biochemical classification. Conclusions: The present family indicates that even in the socalled late onset or acquired 21-OHase deficiency, the enzymatic defect is present and expressed at birth. If so all children detected in neonatal screening program may not need treatment.
Normal ACTH levels in saltlosing congenital adrenal hyperplasia (CAH) with elevated plasma renin concentration (PRC). The effect of mineralocorticoid treatment. 124 Pubertal Growth in Congenital Adrenal Hyperplasia.
Diminished final height was noted in cases of CAE due to 21-hydroxylase deficiency. Overdosage of glucocorticoids in infancy and blunted growth spurts in adolescents were assumed to be the causes. -This study focuses on pubertal growth in 26 female CAH-patients adequately treated with glucoand mineralocorticoids. 17 girls in group I received 20-25 mg/m2 of hydrocortisone and if necessary 0,025-0,15 mg of Sb(-fluorocortisol. 9 girls in group I1 received an additional cyproteroneacetate therapy if bone age (BA) advanced height age (HA) for more than 1 year. Group I: A pubertal growth spurt was found in 14 girls (82,4%) with a peak height velocity of 6-2+1,6 (SD) cm/ yr. In puberty the BA of early treated girls developed slowly. Based on the BA the peak height velocity was therefore even elevated up to 8,72 1,4cm/yr. BA. Group 11: Cyproterone-acetate suppressed symptoms of puberty but did not extinguish growth spurt. During 6,3+1,3 yrs. of treat--ment BA advanced only 4,2+0,7 yrs. However, in this periodheight increased by 20,8_t6,4 cm which corresponds to a mean height velocity of 3,3+0,8 cm/yr., and 4,920,8 cm/yr. BA. In 4 patients adult height had improved by 6,5+1,5cm compared to the prognosis of adult height before treatment. In summary, adequately treated CAH-girls showed normal values for pubertal height velocity, those treated additionally with cyproteroneacetate exhibited improved height yelocity and adult height.
